Preview

Медицинский Совет

Расширенный поиск

Комбинированная терапия артериальной гипертензии

https://doi.org/10.21518/2079-701X-2015-12-18-23

Полный текст:

Аннотация

Статья представляет собой краткий обзор литературных данных, касающихся назначения комбинированной антигипертензивной терапии. Особое внимание уделяется доказательной базе применения фиксированной комбинации лерканидипина и эналаприла, для которой характерны высокая антиги-пертензивная эффективность, низкий уровень побочных эффектов, доказанное органопротективное (прежде всего, нефропротективное) действие и отсутствие негативного влияния на обмен липидов и глюкозы, что позволяет использовать данную комбинацию в любых возрастных группах пациентов, а также у больных, относящихся к группам высокого сердечно-сосудистого риска.

Об авторе

О. О. Большакова
Северо-Западный федеральный медицинский исследовательский центр им. В.А. Алмазова Минздрава России, Санкт-Петербург
Россия


Список литературы

1. Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014; 311(5): 507-520.

2. Amenta F, Peleg E, Tomassoni D et al. Effect of Treatment With Lercanidipine on Heart of Cohen-Rosenthal Diabetic Hypertensive Rats. Hypertension. 2003; 41: 1330-1335.

3. Agrawal R, Marx A, Haller H. Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populatios with uncontrolled hypertension. J. Hypertens 2006; 24: 185-192.

4. Baguet J-P Out-of-of office blood pressure: from management to control. Integrated Blood Pressure Control. 2012: 5 27-34.

5. Bakris GL. Maximizing cardiorenal benefit in the management of hypertension: Achieve blood pressure goals. J Clin Hypertens. 1999; 1: 141-147.

6. Bang LM, Chapman TM, Goa KL. Lercanidipine: a review of its efficacy in the management of hypertension. Drugs 2003; 63: 2449-2472.

7. Barrios V, Escobar C, Echarri R. Fixed combinations in the management of hypertension: perspectives of lercanidipine-enalapril. Vascular Health and Risk Management 2008; 4: 847-853.

8. Barrios V, Escobar S, Navarro A, et al. Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA study. Int J Clin Pract 2006; 60: 1364-1370.

9. Belsey JD. Optimizing adherence in hypertension: a comparison of outcomes and costs using single tablet regimens vs individual component regimens. J Med Econ. 2012; 15: 897-905.

10. Borghi C. Lercanidipine in hypertension. Vascular Health and Risk Management. 2005: 1: 173-182.

11. Breitscheidel L, Ehlken B, Kostev K, et al. Real-life treatment patterns, compliance, persistence. And medications costs in patients with hypertension in Germany. J Med Econ 2012; 15: 155-165.

12. Burnier M. Renal protection with calcium antagonists: the role of lercanidipine. Curr Med Res Opin. 2013; 29: 1727-1735.

13. Canavesi M, Baldini N, Leonardi A, et al. In vitro inhibitory effect of lercanidipine on cholesterol accumulation and matrix metalloproteinases secretion by macrophages. J Cardiovasc Pharmacol 2004; 44: 416-422.

14. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med. 2003; 348: 2407-2415.

15. Corrao G, Parodi A, Nicotra F, Zambon A, Merlino L, Cesana G, Mancia G. Better compliance to antihypertensive medications reduces cardiovascular risk. J Hypertens 2011; 29: 610-618.

16. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihyperten-sive regimen of amlodipine adding perindopril as required versos atenolol adding bendroflu-methiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomized controlled trial. Lancet. 2005; 366: 895-906.

17. Gupta AK, Arshad S, Poulter NR. Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents. A Meta-Analysis. Hypertension 2010; 55: 399-407.

18. Gojanovic B, Feihl F, Liaudet L, et al. Concomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertension. J Renin Angiotensin Aldosterone Syst 2008; 9: 1-9.

19. Hair P, Scott L, Perry C. Fixed-dose combination lercanidipine/enalapril. Drugs 2007; 67: 95-106.

20. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet. 1998; 351: 1755-1762.

21. Jamerson K, Weber M, Bakris G, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428.

22. Lawes CM, Vander Hoorn S. Global burden of blood-pressure-related disease. Lancet, 2008; 371: 1513-1518.

23. Makarounas-Kirchmann K, Glover-Koudounas S, Ferrari P. Results of a meta-analysis comparing the tolerability of lercanidipine and other dihy-dropyridine calcium channel blockers. Clin Ther. 2010; 32: 401-402.

24. Maldonado J, Pereira T, Tavares A. Efficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in Portugal. Drugs 2014; 14: 147-154.

25. Mancia G, Coca A, Chazova I, et al. Effects on office and home blood pressure of the lercan-idipine-enalapril combination in patients with stage 2 hypertension: a European randomized, controlled clinical trial. J Hypertens 2014; 32: 1700-1707.

26. Martinez M, Rizzi E, Castro M, et al. Lercanidipine decreases vascular matrix metal-loproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur J Pharmacol 2008; 599: 110-116.

27. Matsui Y, Ishikawa J, Eguchi K, Shibasaki S, Shimada K, Kario K. Maximum Value of Home Blood Pressure A Novel Indicator of Target Organ Damage in Hypertension. Hypertension. 2011; 57: 1087-1093.

28. Messerli FH. Vasodilatory edema: a common side effect of antihypertensive therapy. Curr Cardiol Reports 2002; 4: 470-482.

29. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The Internationa Verapamil-Trandolapril Study (INVEST): A randomized controlled trial. JAMA. 2003; 290: 2805-2816.

30. Puig J, Calvo C, Luurila O, et al. Lercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPM. J Hun Hypertens 2007; 21: 917-924.

31. Roas S, Bernhart F, Schwarz M, Kaiser W, Noll G. Antihypertensive combination therapy in primary care offices: results of a cross-sectional survey in Switzerland. International Journal of General Medicine. 2014; 7: 549-556.

32. Robles N, Ocon J, Gomez C, et al. Lercanidipine in patients with chronic renal failure: the ZAFRA study. Renal Failure. 2005; 27: 83-92.

33. Robles N, Romero B, Garcia de Vinuesa E, Sanchez-Casado E, Cubero J. Treatment of Proteinuria with Lercanidipine Associated with Renin-Angiotensin Axis-Blocking Drugs. Renal Failure. 2010; 32: 192-197.

34. Rosei EA, Rizzoni D, Muiesan M et al. Effects of candesartan cilexitil and enalapril on inflammatory markers of atherosclerosis in hypertensive patients with non-insulin-dependent diabetes mellitus. J Hypertens 2005; 23: 435-444.

35. Schafer H, Scheunert U. Costs of current anti-hypertensive therapy in Switzerland: an economic evaluation of 3,489 patients in primary care. Swiss Med Wkly 2013; 143: w13854.

36. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265: 3255-3264.

37. Sherrill B, Halpern M, Khan S, Zhang J, Panjab S. Single-Pill vs Free-Equivalent Combination Therapies for Hypertension: A Meta-Analysis of Health Care Costs and Adherence. J Clin Hypertens (Greenwich). 2011; 13: 898-909.

38. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). European Heart Journal (2013) 34, 2159-2219.

39. Todd PA, Goa KL. Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension. Drugs 1992; 31: 346-381.

40. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11000 participants from 42 trials. Am J Med. 2009; 122: 290-300.

41. Zanchetti A. Emerging Data on Calcium-Channel Blockers: The COHORT Study. Clin. Cardiol. 2003; 26 (Suppl. II): II-17-II-20.


Просмотров: 69


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)